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Genetic diversity of viral isolates in human immunodeficiency virus (HIV)-infected individuals varies
substantially. However, it remains unclear whether HIV-related disease progresses more rapidly in patients
harboring virus swarms with low or high diversity and, in the same context, whether high or low diversity is
required to induce potent humoral and cellular immune responses. To explore whether viral diversity predicts
virologic control, we studied HIV-infected patients who received antiretroviral therapy (ART) for years before
undergoing structured treatment interruptions (STI). Viral diversity before initiation of ART and the ability
of the patients to contain viremia after STI and final cessation of treatment was evaluated. Seven out of 21
patients contained plasma viremia at low levels after the final treatment cessation. Clonal sequences encom-
passing the envelope C2V3C3 domain derived from plasma prior to treatment, exhibited significantly lower
diversity in these patients compared to those derived from patients with poor control of viremia. Viral diversity
pre-ART correlated with the viral replication capacity of rebounding virus isolates during STI. Neutralizing
antibody activity against autologous virus was significantly higher in patients who controlled viremia and was
associated with lower pretreatment diversity. No such association was found with binding antibodies directed
to gp120. In summary, lower pretreatment viral diversity was associated with spontaneous control of viremia,
reduced viral replication capacity and higher neutralizing antibody titers, suggesting a link between viral
diversity, replication capacity, and neutralizing antibody activity.
Human immunodeficiency virus type 1 (HIV-1) infection is
characterized by continuous viral replication at a high rate,
which, combined with the error rate of the reverse transcrip-
tase (14, 52), frequent recombination (19, 82), and host selec-
tion pressure, leads to a high genetic diversity in infected in-
dividuals (43, 66, 69, 80, 94). However, the level of diversity
between individual patients can vary considerably. Various vi-
ral and host properties may contribute to the observed diver-
sity: these include differences in virulence, subtype, immuno-
genicity and replication capacity of the transmitted viruses, the
quasispecies composition of the infecting inoculum (transmis-
sion of single versus multiple quasispecies), host genetic fac-
tors such as chemokine receptor polymorphisms, HLA types,
and gender differences (3, 12, 58, 70, 74–76, 83, 84, 88).
Whether or not HIV-related disease progresses more rap-
idly in patients harboring viruses with low or with high diversity
levels is currently not known. While some have argued that
higher viral diversity may induce broader HIV-specific immune
responses, which subsequently could contain viral replication
more efficiently (96), others have found that patients with
limited genetic diversity showed delayed disease progression
and mounted stronger immune responses than rapid progres-
sors (49, 50, 80).
In the simian immunodeficiency virus (SIV) model viral
properties were found to substantially impact disease progres-
sion (40). Likewise, in HIV infection, individuals with high
viral diversity during primary HIV infection progressed more
rapidly (45, 75). Taken together, these findings suggest that
viral properties influence disease progression and are at least
in part responsible for the high variability in viremia control
between HIV-infected individuals.
We have recently shown that viral capacity is a driving factor
in determining the magnitude of viral rebound and viral set
point in chronic HIV-1 infection after cessation of therapy
(90). Here, we investigated whether the diversity of the HIV-1
envelope (env) gene present in plasma before the initiation of
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antiretroviral therapy (ART) predicted the ability of individu-
als to spontaneously control viremia after cessation of long-
term successful ART. We further investigated whether viral
properties, immune correlates, or host genetic factors could be
identified explaining differences in viremia control among pa-
tients. We found that low pretreatment diversity was associ-
ated with spontaneous control of plasma viremia after cessa-
tion of therapy, low viral replication capacity, and strong
neutralizing activity.
(Presented in part at the 10th Conference on Retroviruses
and Opportunistic Infections, 10 to 14 February 2003, Boston,
Massachusetts, abstract 496.)
MATERIALS AND METHODS
Subject selection, samples, and study design. From the 29 subjects enrolled at
the University Hospital Zu¨rich into the Swiss-Spanish Intermittent Treatment
Trial (SSITT) (18), pretreatment plasma samples were available from 26 patients
in the repository of the Swiss HIV Cohort Study. In 24/26 patients, PCR ampli-
fication of a 417-bp fragment spanning the C2 to C3 region of HIV-1 env was
successful. Amplification failed in two patients infected with non-B subtypes
(E/CRF1 and subtype C). Two patients were excluded because they did not
complete the SSITT trial and one because treatment was initiated during primary
HIV infection.
Patients underwent four consecutive STI cycles (2 weeks off and 8 weeks on
treatment), followed by a fifth long treatment interruption (a minimum of 12
weeks off treatment if no adverse effects occurred) during SSITT. None of the
patients experienced drug failure and all had undetectable viral loads (50 RNA
copies/ml) for 6 months before study entry. Results of the clinical trial and
detailed patient characteristics have been reported (18, 21, 23, 61, 63). Written
informed consent was obtained from all patients according to the guidelines of
the Ethics Committee of the University Hospital Zurich. Twenty-one patients
were eligible for the present analysis and the salient characteristics of the study
subjects are shown in Table 1.
RNA extraction and, HIV-1 quantification. RNA extraction from plasma was
performed as described (22). Plasma HIV-1 RNA was quantified using the
Amplicor HIV Monitor test, version 1.5 (Roche Diagnostics, Rotkreuz, Switzer-
land) with modifications resulting in a detection limit of 20 HIV-1 RNA
copies/ml (78).
Quantification of HIV-1 DNA. Extraction of peripheral blood mononuclear
cells (PBMC) and quantification of HIV-1 DNA was performed as previously
described (13, 25). The results were normalized to HIV copies per 106 cells on
the basis of total cellular DNA measurement.
Amplification of HIV-1 env. Reverse transcription-PCR was a modification of
the previously described method (31), which has been adapted to one-tube
reactions in order to minimize the risk of contamination (24, 72, 86). Combined
cDNA synthesis and PCR (RobusT RT-PCR System, Finnzymes, Espoo, Fin-
land) was performed according to the manufacturer’s recommendations. The
outer primers V3Fout (5-CAAAGGTATC CTTTGAGCCA AT-3) and
V3Bout (5-ATTACAGTAG AAAAATTCCC CT-3) were used at 10 pmol
each per reaction. Duplicate 50-l reactions using 25 l starting template RNA
were performed for each sample. This corresponds to the total yield from 800 to
900 l of plasma. The thermocycling conditions were 45 min at 48°C and 2 min
at 94°C, followed by 35 cycles of 30 seconds, 30 seconds, and 60 seconds at 94°C,
56°C, and 72°C, respectively, and 1 cycle of 10 min at 72°C.
For the nested PCR, 1 l of the first-round product was amplified in a
second-round PCR (HotStarTaq Master Mix, Qiagen, Basel, Switzerland) per-
formed according to the manufacturer’s recommendations in a 50-l reaction
volume with 20 pmol each of the modified inner primer V3Fin2 (5-GAACAG
GACC ATGTACAAAT GTCAGCACAG TACAAT-3) and V3Bin (5-GCG
TTAAAGC TTCTGGGTCC CCTCCTGAG-3) and the following cycling con-
ditions: 15 min at 95°C, followed by 35 cycles of 94°C for 30 seconds, 56°C for 30
seconds and, 72°C for 1 min, with a final extension at 72°C for 10 min.
The average misincorporation rate under these nested PCR conditions was
0.18%, as tested by amplification of HIV-1 strain YU2 (GenBank M93258) and
subsequent analysis of 16 clones. This error rate is in line with other reports (48,
74).
Cloning and sequencing. One l of the pooled and purified PCR products was
ligated into the plasmid vector pCR 4 using the TOPO TA cloning system
(Invitrogen, Groningen, Netherlands); 16 individual clones were picked after
bacterial transformation and stored in a microwell plate at 20°C, each in 100 l
of water.; one l of this mix was used in a PCR with 20-l reaction volume, 10
pmol each of the inner primers, and otherwise identical conditions to the second-
round PCR described above. This circumvents the need for overnight cultures
and subsequent plasmid purification. The fidelity of the taq polymerase was
tested by duplicate analysis of 32 clones. Identical sequences were found in the
paired comparisons (error rate: 0/26,000 bp), which indicates that no artifacts are
introduced by the additional PCR step.
One l of each clonal PCR product containing approximately 20 to 30 ng DNA
was sequenced in both directions with the nested primers described above using
BigDye chain terminator chemistry and the automated sequencer ABI 3100
(Applied Biosystems, Rotkreuz, Switzerland).
Phylogenetic analyses. Sequences were edited and aligned with Lasergene
software version 5.06 (DNASTAR Inc., Madison, WI). The alignments were
manually corrected to adjust sequence gaps with the reading frame. Phylogenetic
and molecular evolutionary analyses were conducted using MEGA version 2.1
(41). Genetic distance estimates obtained from the Tamura-Nei 6-parameter
model are reported throughout. Nevertheless, equivalent results were also ob-
tained when simpler nucleotide substitution models like Jukes-Cantor or Kimura
2-parameter were used. Neighbor joining phylogenetic trees were constructed by
MEGA using HXB2 as the reference sequence and bootstrapping (1,000 repli-
cations). Amino acid diversities were estimated by the Poisson Correction model
assuming equal substitution rates and equal amino acid frequencies. Maximum
likelihood phylogenetic trees were constructed by use of DNAML (J. Felsen-
stein, PHYLIP Phylogeny Inference Package version 3.6, distributed by the
author, Department of Genetics, University of Washington, Seattle).
T-cell responses. (i) Assessment of HIV p24-specific CD4 T-cell frequencies.
Peripheral blood lymphocytes (PBL) were depleted of CD8 T cells prior to
analysis using anti-CD8 monoclonal antibody-conjugated magnetic beads (Dynal
United Kingdom Ltd., United Kingdom). Overlapping pooled peptides spanning
full-length HIV p24 protein (5 g/ml, NIBSC, United Kingdom) were used to
determine HIV-specific CD4 T-cell frequencies directly ex vivo by gamma
interferon (IFN-) ELIspot analysis (61, 63). Nonspecific phytohemagglutinin
(PHA) stimulation (5 g/ml) was used as a positive control and medium alone
was used as a negative control in all assays. Results are expressed as specific
spot-forming cells (SFC) per 106 CD8-depleted PBL; background values were
subtracted from the specific response before normalization to 106 CD8-depleted
PBL. A positive response to a given antigen was defined as SFC/106 CD8-
depleted PBL greater than 3 standard deviations above background. Spot quan-
tification was automated and standardized using an ELISPOT plate reader
(Autoimmun Diagnostika, Germany, software version 2.1).
(ii) Assessment of CD8 T-cell responses. Each patient was HLA-typed and
tested repeatedly (mean number of times tested, 16; range, 3 to 26) to assess the
frequency of responsive HIV-specific cytotoxic T lymphocytes (CTLs) in their
peripheral blood lymphocytes. Patients were tested for CTL responses with
synthetic peptides corresponding to previously described HLA class I-restricted
optimal HIV CTL epitopes (61). The epitopes tested are described in the Los
Alamos database (www.hiv.lanl.gov/content/immunology/tables/ctl_summary.html)
in the context of HIV infection, and the exact list of epitopes tested has been
published previously (76). We have evaluated in 58 HIV patients the degree of
correlation between the CD8 T-cell frequencies measured by IFN- ELIspot
using either overlapping peptide pools spanning the entire HIV genome or our
set of 82 previously described CTL epitopes (63) (data not shown). We found a
good correlation (R 0.52, P 0.003) between these approaches, indicating that
our optimal peptide-based analysis of CD8 T-cell frequencies in the present
manuscript is a valid approximation of HIV-specific CD8 T-cell frequencies.
Viral replication kinetics in vitro. (i) Autologous patient viruses. Autologous
virus was isolated from patient PBMCs at the beginning of the fifth interruption
cycle (weeks 42 to 50) by coculturing patient CD4 T cells with stimulated
PBMCs (98). The 50% tissue culture infectious dose and coreceptor usage of the
obtained virus stocks were determined as described previously (90).
(ii) In vitro replicative capacity. Virus inoculum (100 50% tissue culture
infectious doses in 50 l) was added to 12 replicate wells of a 96-well culture
plate containing 2	 105 stimulated PBMCs in 150 l of culture medium. Culture
supernatant was assayed for p24 antigen on days 4, 6, 10, and 14 postinfection by
using an in-house p24 antigen enzyme-linked immunosorbent assay as described
previously (57, 91). As the virus inoculum was not washed out at any stage of the
experiment, the residual input p24 concentration was measured and subtracted
from all test results. Cocultures were fed 100 l of medium on days 6 and 10
postinfection To allow interisolate comparisons, infection experiments for all
isolates were performed on the same day by using the same target cells, a mixture
of three healthy donors, to eliminate distortion of the results by donor cell
variability (90).
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Plasma neutralization activity. Autologous plasma neutralization activity was
evaluated in a PBMC-based assay using replication-competent patient isolates as
described (89). Virus inoculum was incubated with serial dilutions of heat inac-
tivated patient or control plasma for 1 h at 37°C. Stimulated CD8-depleted
PBMC were then infected with aliquots of this preincubation mixture. After 72 h,
cultures were washed three times, then supplemented with medium and freshly
stimulated PBMC. Cultures were incubated for 6 to 10 days and then assayed for
p24 antigen.
Binding antibodies to gp120 antigen. Plasma immunoglobulin G (IgG) titers
to recombinant glycoprotein 120 (gp120) from the JR-FL strain (provided by W.
Olson, Progenics Pharmaceuticals, Tarrytown, NY) were determined by enzyme-
linked immunosorbent assay (ELISA) as described (7). Bound antibody was
detected using alkaline phospatase-conjugated anti-human IgG (Sigma, St.
Louis, MO) and the luminescence-generating CPD-Star system (Applied Bio-
systems, Rotkreuz, Switzerland) as described (89).
Genotypic analysis. PBMC DNA from study subjects was genotyped at CCR2
(V64I), CCR5 (G-2455A), CCR5 (delta 32), CX3CR1 (T280 M), IL-10 (C-
592A), RANTES (G-403A), RANTES (C-28G), macrophage inflammatory pro-
tein 1
 (MIP-1
, T113C), and SDF-1 (3A) genes by using TaqMan allelic
discrimination techniques (Applied Biosystems). The contribution of the various
alleles to HIV-1 susceptibility has been described elsewhere (12, 81, 87). Deter-
mination of HLA genotypes was performed as reported (63, 89).
Data analysis. For each patient, the following viral life history parameters
were calculated.
(i) HIV RNA before HAART. The pretreatment VL corresponds to the plasma
HIV RNA value recorded before highly active ART (HAART) when a plasma
sample was stored and plasma env diversity could be generated at this timepoint.
(ii) Post-STI VL. The post-STI VL value reflects the viral set point, i.e., the
plateau of viremia post-STI, and was determined as the geometric mean of
plasma RNA levels measured after week 40, when a steady state was reached
(usually between weeks 46 and 64). For patient 107, the week 46 data point was
part of a peak and was therefore omitted from the estimation of the plateau.
Overall, 6 to 12 data points were used to calculate the plateau VLs.
(iii) Control of viremia. Patients were classified into a controlling group and a
noncontrolling group according to their abilities to control viremia in the absence
of ART between weeks 40 and 76. Control of viremia was defined as mainte-
nance of a VL of 5,000 RNA copies/ml for at least 8 weeks during this time
period. The cutoff of 5,000 RNA copies/ml was set in the SSITT trial as clinical
endpoint to segregate responders from nonresponders (18).
(iv) In vitro replication capacity (slope between values from days 0 and 6).
Slopes were calculated by performing linear regression analysis using the natural
logarithm of p24 antigen values obtained on days 0, 4, and 6 postinfection.
Statistical analyses. Statistical analyses were performed using GraphPad
Prism version 4 (GraphPad Software, San Diego, CA). Nonparametric tests were
used for group comparisons (Mann-Whitney) and correlations (Spearman).
Nucleotide sequence accession number. All reported sequences have been
deposited in GenBank and assigned accession numbers DQ002026 to DQ002345
and AY656249 to AY656264.
RESULTS
Patient characteristics and cloning of the C2 to C3 region of
HIV env. In total, 336 clones (16 clones per patient, 21 patients)
spanning the C2 to C3 region of the viral envelope were de-
rived from pretreatment plasma HIV RNA. Patient character-
istics are summarized in Table 1. The length of the sequenced
region typically ranged from 343 to 349 bp. Major gaps exceed-
ing 9 bp were found in six clones. However, elimination of
these deleted sequences from distance estimation did not alter
the diversity within the observed groups (0.03% difference).
Viral diversity and phylogenetic reconstruction. Pretreat-
ment nucleotide sequence diversities ranged from 0.7 to 5.5%,
and the amino acid diversities from 1.0 to 10.1%. To obtain
representative samples of quasispecies, RT- and nested PCRs
were performed in duplicate on HIV RNA extracts from 0.8 to
0.9 ml plasma. PCR products were pooled, cloned, and bidi-
rectionally sequenced. All plasma samples tested revealed rel-
atively high plasma virus concentrations (5,000 copies/ml),
making it likely that a range of viral strains rather than one
dominant quasispecies was amplified. Furthermore, there was
no correlation between viral diversity and plasma HIV RNA of
all samples tested (r2 0.002, P 0.84, Fig. 1). Thus, no evidence
was found that low viral diversity was due to low input of HIV
RNA for the samples tested. Taken together, our RT-PCR
strategy and the relatively high plasma HIV RNA levels max-
imize the probability that the sequenced clones are represen-
tative of the actual viral population present in plasma in vivo.
Sequences from each patient formed individual clusters with
high bootstrap values (Fig. 2). Inferred neighbor joining phy-
logenetic trees with the 16 clones from each of the 21 subjects
showed neither mixed interpatient clusters nor clustering with
laboratory-adapted and “primary” HIV clones used in our
laboratory (data not shown). Maximum likelihood trees also
resulted in clear monophyletic clusters for clonal sequences
from each patient (data not shown). We found diversity to be
an intrinsic feature of a given host-virus interaction and not a
simple function of time; the presumed duration of HIV infec-
tion did not correlate with diversity. However, time to infection
could only be estimated within a certain range (Table 1).
Relationship between pretreatment viral diversity and vire-
mia after cessation of treatment. To explore whether viral
diversity had an impact on viral set points patients were clas-
sified into “controlling” and “noncontrolling” groups. Control
of viremia was defined as spontaneous containment of the viral
load to 5,000 RNA copies/ml for at least 8 weeks during the
first 4 months after the last cessation of treatment (Table 1).
FIG. 1. Relationship between plasma virus concentrations and nu-
cleotide sequence diversities observed in 16 clones isolated from each
sample (A). The sequenced clones are representative of the actual viral
populations present in vivo in 21 patients before antiretroviral therapy
due to the high HIV copy number input into the RT-PCRs (total RNA
extracted from 800 to 900 ul plasma was used) (B).
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Pretreatment viral diversity was significantly lower in the
seven patients who controlled viremia compared to that de-
tected in the 14 noncontrollers (median nucleotide diversity:
1.61% for controllers [range, 0.7 to 2.9] and 2.96% for non-
controllers [range, 1.2 to 5.5], P  0.02; median amino acid
diversity: 2.97% for controllers [range, 1.0 to 6.1] and 6.11%
for noncontrollers [range, 2.0 to 10.1], P  0.02) (Fig. 3 A and
3 B). These findings are in agreement with our previous ob-
servation, which showed that containment of viremia in the
controlling group was not induced by STIs but was rather the
consequence of predefined viral and host properties (90). This
was also supported by our finding that pretreatment viral load
in the controlling group (median, 16,927; range, 5,216 to
29,522) tended to be lower than in the noncontrolling group
(median, 33,897; range, 9275 to 164,772, Table 1). If the same
pretreatment viral loads were taken as in the SSITT trial (geo-
metric means of all preexisting pretreatment viral loads), then
these pretreatment viral loads for the present study were sig-
nificantly lower in the controllers (P  0.019) compared to
noncontrollers and these pretreatment viral load measure-
ments did also significantly correlate with plateau viral load
after STIs (P  0.04) (data not shown).
To define whether patients from the controlling group in
general harbored fewer HIV infected cells than noncon-
trollers, we measured proviral DNA levels in peripheral blood
mononuclear cells at the baseline of the first treatment inter-
FIG. 2. Inferred neighbor-joining phylogenetic trees of clonal
HIV-1 env C2-C3 sequences derived from seven patients in the con-
trolling group (A) and 14 patients in the noncontrolling group (B).
Triangles represent the compressed subtrees containing 16 clones iso-
lated from plasma of each patient before antiretroviral therapy. The
length of the triangle corresponds to the respective intrapatient diver-
sity. Bootstrap values are indicated on each branch. The bar denotes
5% nucleotide divergence and diversity; HXB2 was included as exter-
nal reference strain.
FIG. 3. Comparison between controlling and noncontrolling pa-
tients. Pretreatment nucleotide diversity (A) and amino acid diversity
(B) within individual subjects (16 clones each). (C) HIV DNA levels in
peripheral blood mononuclear cells during the first treatment inter-
ruption cycle following 1.6 to 3.9 years of continuous antiretroviral
therapy. Box plots symbolize median value and interquartile range;
whiskers extend over the entire range. P values were calculated by
nonparametric Mann-Whitney test.
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ruption. HIV DNA levels were significantly lower in the con-
trolling group (median, 80 [range, 11 to 1,127] copies per 106
cells) when compared to the noncontrolling group (median,
268 [83 to 1,446] copies per 106 cells, P  0.02) (Fig. 3 C).
Controllers were not treated longer with potent ART (Table
1). Therefore, a more pronounced decay of proviral DNA due
to longer antiretroviral treatment can be excluded and lower
proviral DNA levels in controllers are most likely due to an
inherent limited viral replication capacity of viruses from con-
trollers, when compared to noncontrollers, which is further
supported by the same pattern found for pretreatment viral
loads between groups (Table 1).
Relationship between in vitro replicative capacity and pre-
treatment env diversity. We have recently reported that the in
vitro replicative capacity is a determinant of viral rebound and
set point in chronic infection after cessation of therapy (90).
Here, we explored the extent to which viral diversity is a de-
fining characteristic of a virus population and whether, in turn,
this predicts the fitness of a given virus swarm. To this end, we
investigated the relationship between viral diversity, measured
before the initiation of ART and the replicative capacity of
virus isolates emerging several years later. The median time
interval between determination of plasma env diversity and
replication capacity during viral rebound of the last treatment
interruption in SSITT was 41 months (range, 30 to 58 months).
We found that the extent of pretreatment nucleotide env di-
versity was significantly correlated with the replication capacity
determined years later (r2  0.26, P  0.04, Fig. 4). Thus, we
were able to demonstrate a link between virus swarms with a
greater genetic diversity and virus isolates with higher replica-
tion capacity.
Relationship of pretreatment plasma env diversity, host ge-
netic factors and adaptive immune responses. In the analyses
presented so far we have demonstrated that the replicative
capacity of a patient’s virus isolate, the genetic diversity of the
virus and the patient’s viral set point are significantly depen-
dent on each other. However, thus far we have not gained
insight into what determines whether a virus isolate manifests
itself in a given host with high or low replicative capacity.
Various innate and adaptive immune responses and genetic
host factors have been demonstrated to affect viral fitness and
disease progression.
In a first analysis we assessed if polymorphisms of genetic
loci associated with faster or slower disease progression have
an impact on viral diversity. To this end, patients were strati-
fied according to the median diversity determined in our co-
hort and probed for polymorphisms associated with slow or
rapid disease progression. We evaluated nine genetic polymor-
phisms: CCR2 (V64I), CCR5 (G-2455A), CCR5 (delta 32),
CX3CR1 (T280 M), IL-10 (C-592A), RANTES (G-403A),
RANTES (C-28G), MIP-1
 (T113C), and SDF-1 (3A) (33,
34, 56, 83, 92, 95), but none of these genes was found to be
associated with either higher or lower genetic diversity.
A similar analysis was performed for HLA class I and II
alleles that have previously been shown to be protective against
disease progression (HLA-A*02, A*6802, A*11, B*27, B*51,
B*57, B*58, Cw*08, and DRB1*01) or were found to be pre-
dictive for faster disease progression (HLA-A23, B*08,
B*3501, B*45, B*53, and Cw*04) (11, 12, 47, 59, 76). Again, no
correlation between HLA types associated with slower or
faster disease progression and the degree of pretreatment viral
diversity was found. Despite the fact that host genotypes tested
in our patients did not explain differences in viral diversity,
respectively in controlling viremia, we cannot rule out the
possibility that host genotype exerts an influence. Indeed, ef-
fects of genetic polymorphisms on viral replication are rela-
tively subtle and can generally only be demonstrated reliably in
large patient cohorts, and multiple polymorphisms may act in
concert. Thus, effects by genetic polymorphisms on viral rep-
lication in our small cohort could only be expected to be
demonstrable, if there is an absolute association between par-
ticular alleles and viral replication.
Pretreatment viral diversity and cellular immune responses.
We previously studied CTL responses during the SSITT trial.
Although there was an increase in the magnitude and breadth
of cellular immune responses over the course of treatment
interruptions, these variables were not associated with control
of viremia (18, 61, 63). Here we specifically investigated
whether controlling patients with low viral diversity in C2V3C3
would exhibit greater CTL responses compared to noncontrol-
ling patients with higher C2V3C3 diversity. HIV-specific CTL
responses were measured at week 0 (baseline), week 39 (be-
fore the fifth treatment interruption) and week 50 to 52 (dur-
ing the final treatment interruption).
In line with the results of the larger patient group in the
SSITT trial (63), no significant difference in magnitude (Fig. 5
A) or breadth (Fig. 5 B) of the CTL response was found
between controlling and noncontrolling patients. During the
STI trial, a transient increase in HIV Gag p24-specific CD4
T-cell responses occurred (63), which was sustained in patients
who had lower pretreatment viral loads. Here, we investigated
whether patients with low pretreatment viral diversity were
able to mount larger HIV-specific CD4 T-cell responses
when compared to patients with high viral diversity. However,
no significant differences in CD4 T helper responses between
these groups were apparent (Fig. 5 C).
FIG. 4. Correlation between pretreatment viral diversity and in
vitro growth characteristics of virus isolated during the fifth treatment
interruption. Replication capacity was derived from the profile of HIV
p24 antigen production in cultures by linear regression (slope of nat-
ural logarithms of p24 levels over 6 days). Spearman correlation anal-
ysis: r2  0.26, P  0.04, n  16.
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Envelope diversity and neutralizing antibody response. We
next investigated if the neutralizing antibody response was
associated with viral diversity. Neutralizing activity of plasma
obtained at week 2 of the first treatment interruption was
measured against the autologous virus isolate. We found that
higher plasma neutralizing activity against autologous virus
was associated with lower pretreatment nucleotide sequence
diversity (r2  0.24, P  0.034, Fig. 6 B) and amino acid
diversity (r2  0.25, P  0.028). In contrast, no association
between diversity and titers of antibodies binding to mono-
meric anti-gp120 was found (Fig. 6 C). This finding under-
scores our previous observation that neutralizing antibody ti-
ters were higher in controlling than in noncontrolling patients
(P  0.031, Fig. 6 A) (89).
DISCUSSION
It has been a longstanding debate as to whether HIV-related
disease progresses more rapidly in patients harboring viruses
with low or with high diversity and to what extent differences in
diversity are related to host genetics and immune responses.
To investigate this issue further, we performed a comprehen-
sive virological, immunological, and genetic data analysis in
chronically HIV-1-infected patients enrolled for years in the
Swiss HIV Cohort Study: these patients were studied longitu-
FIG. 5. HIV-specific cellular immune responses in patients exhib-
iting low (lo  below median) and high (hi  above median) pretreat-
ment viral diversity determined at week 0 (baseline of STI), week 39
(before the fifth treatment interruption) and week 50 (during the last
treatment interruption). Magnitude of CD8 cytotoxic T-cell response
(CTL) expressed as total spot forming colonies (SFC) per 106 cells (A);
6–31 (median 18) different peptides were tested. The breadth of the
CD8 CTL response is indicated as the percentage of peptides tested
that induced a response 50 SFC/106 cells (B). Magnitude of the
HIV-specific CD4 T-cell response expressed as SFC per 106 CD8-
depleted PBMC (C).
FIG. 6. Comparison of 70% neutralizing titers found in 7 control-
ling and 12 noncontrolling patients (A). Neutralization activity of pa-
tient plasma derived from the first STI cycle was tested against autol-
ogous virus isolates derived during the fifth cycle. Dashed line
represents the detection limit. Lower pretreatment diversity was cor-
related with higher neutralizing antibody activity (B, r2  0.24, P 
0.03, n  19), whereas no correlation between diversity and titers of
antibodies binding to monoclonal anti-gp120 was found (C).
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dinally prior to ART, during continuous ART, and while they
subsequently participated in a recent structured treatment in-
terruption trial (Swiss-Spanish Intermittent Therapy Trial) (18,
21, 23, 24, 55, 61 to 63, 76, 89, 90, 99, 100). Specifically, we
wanted to determine whether envelope diversity from plasma
HIV-1 RNA before initiation of antiretroviral treatment was
predictive of an individual’s ability to spontaneously control
plasma viremia after cessation of ART. In addition, we probed
viral properties and host characteristics, such as adaptive im-
mune responses and host genetic factors, in order to elucidate
the underlying mechanisms that steer viral diversity.
The key finding of these analyses was that envelope diversity
before initiation of ART was significantly lower in patients who
subsequently controlled plasma viremia during treatment in-
terruption. This low pretreatment diversity observed in con-
trollers implies that, in drug-naı¨ve patients, viral strains had
replicated to a lesser extent in controlling patients than in
noncontrollers, who exhibited higher pretreatment diversities.
Indeed, the fact that the degree of pretreatment env diversity
not only predicted viremia upon cessation of ART but was also
significantly correlated with the in vitro replication capacity of
the viral isolates rebounding during this treatment interruption
strongly suggests that the diminished replication properties of
these viruses were most likely present before treatment and
remained so. This view is supported further by the finding that
PBMC from patients who controlled viremia and had low pre-
treatment diversity also harbored low levels of proviral DNA at
the beginning of the treatment interruption. Thus, the viruses
present in these patients not only replicated to a lesser extent,
but also established a latent reservoir of reduced size (85, 101),
which subsequently led to limited viral rebound and lower viral
load plateaus during and after SSITT (18, 21, 25, 26, 100).
The questions of what causes lower diversity and how this
relates to viral replication capacity then arise. HIV-specific
cellular immune responses are thought to play a major role in
controlling viremia (35, 44, 66, 77). However, although we have
observed significant increases in HIV-specific CTL and
T-helper responses in SSITT, those increases did not predict
control of viremia but rather reflected antigen-driven expan-
sions of T-cell responses due to viral recrudescence (18, 61,
63). Lacking correlation of HIV-specific immune responses,
mostly assessed by antigen-induced IFN- production, with
control of plasma viremia were also described in studies per-
formed by other groups (1, 5, 10, 38), suggesting that there is
not direct correlation between the magnitude of the HIV-
specific T-cell response, as measured by current techniques,
and the level of viral replication. Such a linear correlation
would actually be unlikely to exist, since both antigen load (i.e.,
the level of viral replication) and HIV-specific T-cell immunity
influence each other. Furthermore, it is likely that current
techniques to measure overall HIV-specific immune responses
with consensus or even with autologous HIV peptides may not
adequately describe the in vivo functionality of those cells in
the absence of knowledge about the contemporaneous full-
length viral sequences. To this aim, longitudinal studies have to
be performed starting at primary HIV infection, in which serial
complete autologous viral sequencing is performed in conjunc-
tion with assessing T-cell responsiveness to contemporaneous
T-cell antigens. Such studies have been performed and clearly
indicated that CTL-driven epitope variation often occurs at
various stages of infection (9, 36, 39, 43, 60, 64, 66).
In some of these studies it was shown that selection of CTL
escape viruses was associated with reduced viral control and
with loss of viral fitness (4, 27, 29).
Thus, CD8 T-cell responses are clearly also involved in
driving viral diversity. As such, the type of analysis of T-cell
responses and viral diversity in this study does not address this
question; however it indicates that there are no overall differ-
ences in the magnitude of T-cell frequencies between our pa-
tients with low or high env diversity.
Furthermore, it is conceivable that current techniques to
measure HIV-specific immune responses may not adequately
reflect the critical function of these cells that mediates control
of HIV replication or that defense against HIV relies more on
other adaptive or innate mechanisms (6, 71, 97). Interestingly,
however, when exploring the humoral immune response we
found a clear association between low pretreatment diversity
and strong neutralizing antibody titers against autologous virus
at baseline of the SSITT protocol.
Two possible scenarios can be envisioned: First, patients
with low pretreatment diversity could have raised substantial
neutralizing antibody responses early during infection and,
subsequently were able to contain viral replication to a certain
degree. In support of this, it has recently been shown that
during and after primary infection, a neutralizing antibody
response is generated that exerts a strong selection pressure on
HIV env and leads to the rapid emergence of viral escape
mutants (69, 94). Thus, it can be hypothesized that the con-
tainment of viremia seen in a subset of our patients might have
been due to the continuous generation of neutralizing antibod-
ies that lead to sustained suppression of viremia (32).
Second, patients with low pretreatment diversity may have
been infected by viruses of low pathogenicity, which subse-
quently allowed a strong neutralizing antibody response to
emerge. Over recent years, evidence has accumulated that
properties of the infecting virus are important determinants of
disease progression (8, 15, 16, 20, 30, 37, 42, 67, 79, 93). Kimata
et al. showed that infection of macaques with SIV strains,
derived from SIV-infected macaques at different time points
after infection, exhibited differential pathogenicity in the new
host; viruses derived from later stages being more pathogenic.
This difference in pathogenicity was not due to the emergence
of syncytium-inducing viruses but was attributed to the fact
that animals infected with the early and intermediate phase
viruses were able to raise significant neutralizing antibody re-
sponses, while the rapid progressors infected with late stage
viruses failed to do so (40).
Further evidence that viral properties are important comes
from the same group, which showed that patients who harbor
viruses with higher diversity during primary infection, most
likely representing infection events by multiple viruses, have
higher viral set points and faster disease progression than pa-
tients with low diversity (45, 75). Taken together, one could
hypothesize that our patients who harbored viruses with low
level replication kinetics and low pretreatment diversity were
primarily infected with viruses of reduced pathogenicity, which
then allowed a more prominent neutralizing antibody response
to develop that aided subsequent control of viremia. The fact
that viruses with lower pretreatment diversity and reduced
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replication capacity also exhibited increased sensitivity to
-chemokines (90) supports the view that these viruses were
intrinsically different from viruses derived from noncontrollers
independently of the immunological response (data not
shown).
Nevertheless, other factors that have been associated with
better control of viral replication in large-cohort studies, such
as host genetic polymorphisms and HLA types, must also be
considered (12). In this study, neither genetic host polymor-
phisms in the genes for CCR2, CCR3, CCR5, RANTES, MIP-
1
, SDF-1, or IL-10 nor HLA genotypes were associated with
the degree of viral pretreatment diversity. In addition, no ma-
jor variants harboring mutations associated with drug resis-
tance were detected either in controllers or in noncontrollers
(55, 99), thus excluding potential differences in replication
capacity caused by resistance to antiretroviral drugs (51, 65,
68).
Our data are in agreement with Markham (50), Mani (49),
and McNearney (54), who found that, among seroconverters,
rapid progressors exhibited higher viral diversity than moder-
ate or slow progressors. In contrast, several studies have found
the opposite: rapid progression associated with low viral diver-
sity (2, 17, 28, 46, 53, 96).
For example, Wolinsky et al. (96) described stronger HIV-
specific CTL responses in patients with high env diversity and
lower viral set points compared to rapid progressors, who ex-
hibited low diversity and weak CTL responses. However, we
observed no relationship between either HIV-specific CD8
CTL responses or CD4 T helper cell responses and viral
diversity (Fig. 5). What could be the reasons for such conflict-
ing results? In many of the earlier studies, only limited num-
bers of patients were studied. Furthermore, patients were
mostly selected from large cohorts according to extremes of
disease progression, e.g., rapid CD4 cell loss versus stable CD4
count. This strategy bears a high potential to also select for
other factors associated with rapid or slow disease progression,
such as certain chemokine receptor polymorphisms and HLA
alleles, which now are known to influence HIV disease pro-
gression substantially in some cases. Host genetic factors and
viral determinants were not described in most of these studies.
Thus, strong bias due to unknown viral and host factors may
have been introduced and may at least in part have been
responsible for discrepant findings and therefore comparability
of the conflicting studies is limited.
We acknowledge the potential limitations of our study. Our
study was relatively small, limiting the power of the genetic
analysis, with a risk of beta-type error (concluding that there
was no difference, although in fact one did exist).
In addition, we could not follow patients from the time of
seroconversion, and thus we cannot exclude completely that
controlling patients were infected for shorter time periods.
Nevertheless, the time between when infection occurred and
when antiretroviral treatment was started could be estimated
(Table 1). We found no significant difference when the num-
bers of patients with time to infection 24 months and 24
months were compared (P  0.4) between controllers and
noncontrollers. Moreover, a lack of influence of infection time
is further supported by the observation that in the controllers
we have found very low diversities (1%) in three patients,
which were at the most conservative estimate infected for at
least 1 to 2 years when diversity was measured, whereas such
low diversity was not seen in any of the noncontrollers. Re-
cently, we have observed diversities of 1% (median, 0.42;
range, 0.26 to 0.96) in 10 subjects with well-characterized pri-
mary HIV infection (73). In the noncontrollers, diversities of
1% were never detected despite the fact that in this group
estimates of time from infection to determination of diversity
could also be estimated to 12 to 24 months. Taken together the
available data shows no suggestion that controllers were in-
fected for a shorter period of time than the noncontrollers.
Moreover, the prospective nature of our study and the cor-
relation found between pretreatment diversities, in vitro rep-
lication capacity and neutralizing antibodies (representing dif-
ferent assay types at different time points) make a bias based
on patient selection even more unlikely. All viruses studied
were R5 users, and during STIs no coreceptor switch was
detected (90); also, all but one were subtype B, thus further
reducing potential confounding factors (58).
In conclusion, we found that low pretreatment viral diversity
was associated with better spontaneous control of plasma vire-
mia after the last treatment interruption. The observation that
viruses rebounding from patients with low pretreatment diver-
sity years after successful ART demonstrated a reduced ability
to replicate ex vivo, independent of the host cellular immune
response, suggest that intrinsic viral properties, at least partly,
were responsible for reduced viral replication, which resulted
in lower viral diversity. Whether the higher neutralizing anti-
body titers found in controlling patients are cause or conse-
quence of this reduced viral diversity and impaired replication
capacity will need to be determined in longitudinal serocon-
verter studies. Nevertheless, our data suggest that viral char-
acteristics in conjunction with neutralizing antibody activity are
participating in shaping the course of HIV disease.
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